Studies on novel 4β-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents

European Journal of Medicinal Chemistry

Volumn 43, Issue 10, 2008, Pages 2067-2072

  Bhat, Bilal A ^a   Reddy, P Bhaskar ^a   Agrawal, Satyam Kumar ^a   Saxena, A K ^a   Kumar, H M Sampath ^a   Qazi, G N ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Cancer cell lines; N prop 2 yn 1 ylanilines; Podophyllotoxin; Regioselectivity

Indexed keywords

9 [4 [(3 NITROPHENYLAMINO)METHYL] 1,2,3 TRIAZOL 1 YL] 5 (3,4,5 TRIMETHOXYPHENYL) 5,8,8A,9 TETRAHYDRO 5AH FURO[30,40:6,7]NAPHTHO[2,3 D][1,3]DIOXOL 6 ONE; ANTINEOPLASTIC AGENT; COPPER; PODOPHYLLOTOXIN DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; PODOPHYLLOTOXIN;

ARTICLE; CANCER CELL CULTURE; CATALYSIS; CYCLOADDITION; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; CHEMISTRY; ENZYME SPECIFICITY; IC 50; STEREOISOMERISM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; PODOPHYLLOTOXIN; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TRIAZOLES;

EID: 53149088194     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.09.015     Document Type: Article

References (22)

1. Jardine I. In: Cassady J.M., and Douros J. (Eds). Anticancer Agents Based on Natural Product Models (1980), Academic Press, New York 319
2. Lee K.H., Beers S.A., Mori M., Wang Z., Kuo Y.H., Li L., Liu S.Y., Chang J.Y., Han F.S., and Chen Y.C. J. Med. Chem. 33 (1990) 1364-1368
3. Wang Z.Q., Kuo Y.H., Schnur D., Bowen J.P., Liu S.Y., Han F.S., Cheng Y.C., and Lee K.H. J. Med. Chem. 33 (1990) 2660-2666
4. Macdonald T.L., Lehenert E.K., Loper J.T., Chow K.C., and Ross W.E. DNA Topoisomerase in Cancer (1991), Oxford University, New York p. 119
5. Issell B.F. Cancer Chemother. Pharmacol. 7 (1982) 73-80
6. Rassmann I., Schrodel H., Schilling T., Zucchetti M., Kaeser-Frohlich A., Rastetter J., and Hanauske A.R. Invest. New Drugs 14 (1996) 379-386
7. Van Maanen J.M.S., Retel J., De Vries J., and Pinedo H.M. J. Natl. Cancer Inst. 80 (1988) 1526-1533
8. Hainsworth J.D., Williams S.D., Einhorn L.H., Birch R., and Greco F.A. J. Clin. Oncol. 3 (1985) 666-671
9. Liu S.Y., Hwang B.D., Haruna M., Imakura Y., Lee K.H., and Cheng Y.C. Mol. Pharmacol. 36 (1989) 78-82
10. Zhou X.M., Wang Z.Q., Chang J.Y., Chen H.X., Cheng Y.C., and Lee K.H. J. Med. Chem. 34 (1991) 3346-3350
11. Xiao Z., Xiao Y.D., Golbraikh A., Tropsha A., and Lee K.H. J. Med. Chem. 45 (2002) 2294-2309
12. Van Vilet D.S., Tachibana Y., Bastow K.F., Huang E.S., and Lee K.H. J. Med. Chem. 44 (2001) 1422-1428
13. Terada T., Fujimoto K., Nomura M., Yamashita J., Wierzba K., Yamazaki R., Shibata J., Sugimoto Y., Yamada Y., Kobunai T., Takeda S., Minami Y., Yoshida K., and Yamaguchi H. J. Med. Chem. 36 (1993) 1689-1699
14. W. Choy, Genelabs Technologies, personal communication.
15. Utsugi T., Shibata J., Sugimoto Y., Aoyagi K., Wierzba K., Kobunai T., Terada T., Ohhara T., Tsuruo T., and Yamada Y. Cancer Res. 56 (1996) 2809-2824
16. Cho S.J., Tropsha A., Suffness M., Cheng Y.C., and Lee K.H. J. Med. Chem. 39 (1996) 1383-1395
17. Cao C.N., Chen Y.Y., Wang Y.G., and Chen Y.Z. Chin. Chem. Lett. 10 12 (1999) 1003-1006
18. Kolb H.C., Finn M.G., and Sharpless K.B. Angew. Chem., Int. Ed. 40 (2001) 2004-2021
19. Huisgen R. Proc. Chem. Soc. 6 (1961) 357-369
20. Kamal A., Laxman N., and Ramesh G. Bioorg. Med. Chem. Lett. 10 (2000) 2059-2062
21. Skehan P., Storeng R., Seudiero D., Monks A., Memahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107-1112
22. Kaur M., Singh K., Rup P.J., Kamboj S.S., Saxena A.K., Sharma M., Bhagat M., Sood S.K., and Singh J. J. Biochem. Mol. Biol. 39 4 (2006) 432-440